The Transformed Minds Pod
The Transformed Minds Pod
Podcast Description
Transformed Minds is a podcast dedicated to reshaping how we understand and approach mental health and substance use. Through evidence-based discussions, real stories, and expert interviews, we create a space for learning, reflection, and transformation.
Hosted by theprayingpsychiatrist, a physician, researcher, and advocate for community and global mental health, this platform bridges evidence-based medicine, clinical insight and lived experience. Whether you're a provider, trainer, policymaker, patient, or loved one—this podcast is for you.
Let’s learn, heal and transform – together!
Podcast Insights
Content Themes
The podcast delves into essential themes surrounding mental health and addiction, focusing on topics like integration of addiction care into mental health services, the impact of dual diagnoses, and the intersection of faith and healing. For instance, an episode featuring Dr. Ayana Jordan discusses innovative models of care for co-occurring disorders based on her research, emphasizing the necessity of embedding addiction specialists into community mental health.
Transformed Minds is a podcast dedicated to reshaping how we understand and approach mental health and substance use. Through evidence-based discussions, real stories, and expert interviews, we create a space for learning, reflection, and transformation.
Hosted by theprayingpsychiatrist, a physician, researcher, and advocate for community and global mental health, this platform bridges evidence-based medicine, clinical insight and lived experience. Whether you’re a provider, trainer, policymaker, patient, or loved one—this podcast is for you.
Let’s learn, heal and transform – together!
Can psilocybin help patients with treatment-resistant depression and what does the latest clinical evidence mean for people dealing with both depression and addiction?
In this episode of The Transformed Minds (Host Rx), psychiatrist Dr. O breaks down a landmark 2022 NEJM phase II randomized, double-blind, multicenter trial examining psilocybin therapy for treatment-resistant depression (TRD).
Dr. O explains what qualifies as TRD, walks through the trial's three-arm dosing design (1 mg, 10 mg, and 25 mg plus structured psychological support), and interprets the primary outcome, MADRS score change at three weeks. The 25 mg dose showed statistically significant and clinically meaningful improvement, but the story gets more complex by week 12.
This episode is especially valuable for clinicians, patients, and advocates navigating dual diagnosis care co-occurring depression and substance use disorders. Dr. O covers:
– psilocybin-assisted therapy- treatment-resistant depression, – MADRS depression scale, – psychedelic safety- mental health equity- substance use disorder and depression
Whether you're a mental health professional, someone living with TRD, or simply following the rapidly evolving conversation around psychedelic medicine, this episode gives you the evidence-based framework to think critically, not just hopefully about what psilocybin can and cannot do right now.
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.